Stock News

Northrim BanCorp, Inc. (NRIM) Reaches $38.05 52-Week High; 7 Analysts Bullish AxoGen, Inc. (AXGN)

The stock of Northrim BanCorp, Inc. (NASDAQ:NRIM) hit a new 52-week high and has $41.47 target or 9.00% above today’s $38.05 share price. The 8 months bullish chart indicates low risk for the $260.77M company. The 1-year high was reported on Dec, 4 by Barchart.com. If the $41.47 price target is reached, the company will be worth $23.47M more. The stock increased 3.54% or $1.3 during the last trading session, reaching $38.05. About 8,689 shares traded. Northrim BanCorp, Inc. (NASDAQ:NRIM) has risen 10.30% since December 4, 2016 and is uptrending. It has underperformed by 6.40% the S&P500.

Among 7 analysts covering AxoGen (NASDAQ:AXGN), 7 have Buy rating, 0 Sell and 0 Hold. Therefore 100% are positive. AxoGen had 16 analyst reports since August 11, 2015 according to SRatingsIntel. The firm has “Outperform” rating given on Thursday, November 2 by Leerink Swann. The firm has “Buy” rating given on Monday, August 21 by Cantor Fitzgerald. The firm earned “Buy” rating on Tuesday, November 22 by Lake Street. Wedbush maintained the shares of AXGN in report on Monday, November 7 with “Outperform” rating. The stock of AxoGen, Inc. (NASDAQ:AXGN) earned “Hold” rating by Lake Street on Thursday, November 3. Wedbush maintained it with “Outperform” rating and $5 target in Friday, August 28 report. The firm has “Outperform” rating given on Tuesday, November 21 by Leerink Swann. The stock of AxoGen, Inc. (NASDAQ:AXGN) has “Hold” rating given on Tuesday, August 11 by Zacks. Wedbush maintained the stock with “Buy” rating in Tuesday, November 21 report. Roth Capital maintained AxoGen, Inc. (NASDAQ:AXGN) on Monday, September 11 with “Buy” rating. See AxoGen, Inc. (NASDAQ:AXGN) latest ratings:

30/11/2017 Broker: Jefferies Rating: Buy New Target: $35 Initiates Coverage On
21/11/2017 Broker: Leerink Swann Old Rating: Outperform New Rating: Outperform Old Target: $26 New Target: $30 Maintain
21/11/2017 Broker: Lake Street Rating: Buy New Target: $26.0
21/11/2017 Broker: Wedbush Rating: Buy New Target: $27.0 Maintain
02/11/2017 Broker: Leerink Swann Rating: Outperform Old Target: $23 New Target: $26 Maintain
11/09/2017 Broker: Roth Capital Rating: Buy New Target: $21.0 Maintain
21/08/2017 Broker: Cantor Fitzgerald Rating: Buy Maintain
31/07/2017 Broker: Leerink Swann Rating: Outperform New Target: $22 Initiates Coverage On
30/06/2017 Broker: Cantor Fitzgerald Rating: Overweight New Target: $18 Initiates Coverage On

The stock increased 1.52% or $0.4 during the last trading session, reaching $26.8. About 184,871 shares traded. AxoGen, Inc. (NASDAQ:AXGN) has risen 181.49% since December 4, 2016 and is uptrending. It has outperformed by 164.79% the S&P500.

AxoGen, Inc. provides surgical solutions for peripheral nerve injuries. The company has market cap of $913.71 million. The companyÂ’s surgical nerve repair solutions include Avance Nerve Graft, an off-the-shelf processed human nerve allograft for bridging severed nerves without the comorbidities associated with a second surgical site; AxoGuard Nerve Connector, a porcine submucosa extracellular matrix coaptation aid for tensionless repair of severed nerves; and AxoGuard Nerve Protector, a porcine submucosa ECM product that is used to wrap and protect injured peripheral nerves, as well as reinforces the nerve reconstruction while preventing soft tissue attachments. It currently has negative earnings. The Company’s solutions also comprise Avive Soft Tissue Membrane, a minimally processed human umbilical cord membrane that is used as a resorbable soft tissue covering to separate tissues and modulate inflammation in the surgical bed.

Investors sentiment decreased to 1.13 in Q2 2017. Its down 0.05, from 1.18 in 2017Q1. It worsened, as 8 investors sold Northrim BanCorp, Inc. shares while 22 reduced holdings. 14 funds opened positions while 20 raised stakes. 4.81 million shares or 0.36% more from 4.79 million shares in 2017Q1 were reported. Renaissance Technology Llc has 70,900 shares for 0% of their portfolio. Dalton Greiner Hartman Maher reported 0.09% of its portfolio in Northrim BanCorp, Inc. (NASDAQ:NRIM). Fuller Thaler Asset Incorporated invested in 19,884 shares. Bancorporation Of America Corporation De accumulated 5,222 shares. Nationwide Fund has 6,214 shares for 0% of their portfolio. Dimensional Fund Limited Partnership invested in 522,570 shares or 0.01% of the stock. Northern Trust reported 0% of its portfolio in Northrim BanCorp, Inc. (NASDAQ:NRIM). Tiaa Cref Invest Mgmt Ltd accumulated 19,620 shares. First Tru Advisors L P has invested 0% in Northrim BanCorp, Inc. (NASDAQ:NRIM). Morgan Stanley, New York-based fund reported 26,042 shares. Bessemer Grp Incorporated holds 0% or 9,775 shares in its portfolio. Legal & General Group Public Limited Co has invested 0% in Northrim BanCorp, Inc. (NASDAQ:NRIM). Meeder Asset Mgmt reported 839 shares. Wells Fargo Mn owns 6,956 shares. Strs Ohio invested in 0% or 20,200 shares.

Northrim BanCorp, Inc. operates as bank holding firm for Northrim Bank that provides commercial banking services and products to businesses and professional individuals primarily in Alaska. The company has market cap of $260.77 million. The firm operates in two divisions, Community Banking and Home Mortgage Lending. It has a 18.93 P/E ratio. It offers various deposit products, including noninterest-bearing checking accounts and interest-bearing time deposits, checking accounts, and savings accounts, as well as money market deposit accounts, certificates of deposit, and courier noncash deposits.

Analysts await Northrim BanCorp, Inc. (NASDAQ:NRIM) to report earnings on January, 29. They expect $0.51 EPS, 0.00% or $0.00 from last year’s $0.51 per share. NRIM’s profit will be $3.50 million for 18.65 P/E if the $0.51 EPS becomes a reality. After $0.79 actual EPS reported by Northrim BanCorp, Inc. for the previous quarter, Wall Street now forecasts -35.44% negative EPS growth.

Receive News & Ratings Via Email - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with our FREE daily email newsletter.


Leave a Reply

Your email address will not be published. Required fields are marked *